Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives

Area of Science:

• Gastroenterology
• Nanotechnology
• Pharmacology

Background:

• Ulcerative colitis involves colon inflammation and increased pathogen permeability due to thin mucus layers.
• Conventional treatments often fail to target the colon effectively, leading to poor therapeutic outcomes and reduced quality of life.
• Existing nanocarriers lack specificity and are cleared rapidly, hindering effective drug accumulation at diseased sites.

Purpose of the Study:

• To review the advancements in responsive nanocarrier drug delivery systems for ulcerative colitis.
• To highlight the potential of smart nanomaterials for targeted and on-demand drug release in the colon.
• To discuss the benefits of multi-responsive nanocarriers in enhancing drug delivery and therapeutic efficacy.

Main Methods:

• Exploration of various responsive nanocarrier systems, including pH, ROS, enzyme, and thermo-responsive systems.
• Investigation of nanotechnology scaffolds for formulating targeted drug delivery vehicles.
• Analysis of multi-responsive and derivatized nanocarrier systems for improved biological interaction.

Main Results:

• Responsive nanocarriers enable selective drug release at inflamed colon sites, minimizing systemic absorption.
• Smart nanomaterials improve drug targeting, leading to enhanced therapeutic concentrations in diseased tissues.
• Multi-responsive systems demonstrate increased interaction with biological tissues and improved cellular uptake of therapeutic agents.

Conclusions:

• Responsive nanocarriers represent a promising strategy for overcoming the challenges in ulcerative colitis treatment.
• These advanced drug delivery systems offer on-demand drug release, improving efficacy and reducing side effects.
• Further development of responsive nanocarriers holds significant potential for advancing ulcerative colitis therapy.